3rd Sep 2009 11:42
AGI Therapeutics PLC
Notification of Results
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company, will be announcing its interim results for the six months ended 30 June 2009 on Tuesday, 22 September 2009.
Contact Information:
|
AGI Therapeutics plc. |
Tel: +353 1 449 3254 |
|
David Kelly, Chief Financial Officer |
|
|
Financial Dynamics - UK |
Tel: +44 (0) 20 7269 7205 |
|
Jonathan Birt/John Dineen |
|
|
Financial Dynamics - Ireland |
Tel: +353 (0) 1 66 33 602 |
|
Niamh Lyons |
|
|
Piper Jaffray Limited Neil Mackison Will Carnwath |
Tel: +44 (0) 20 3142 8700 |
|
Davy John Frain |
Tel: +353 (1) 614 8761 |
Notes to Editors:
About AGI Therapeutics plc
AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastrointestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
For further information please see www.agitherapeutics.com
Related Shares:
Potentially Ai